IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
82 hedge funds and large institutions have $153M invested in IGM Biosciences in 2024 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 40 increasing their positions, 15 reducing their positions, and 18 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 15
140% more call options, than puts
Call options by funds: $271K | Put options by funds: $113K
2.39% less ownership
Funds ownership: 68.57% → 66.18% (-2.4%)
6% less funds holding
Funds holding: 87 → 82 (-5)
28% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 18
31% less capital invested
Capital invested by funds: $220M → $153M (-$67.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$2.14M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.6M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.18M |
| 4 |
BlackRock
New York
|
+$1.07M |
| 5 |
CC
Corton Capital
Carrying Place,
Ontario, Canada
|
+$542K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.05M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.27M |
| 3 |
Millennium Management
New York
|
-$2.6M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$758K |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$233K |
IGMS Hedge Fund Activity: Q2 2024 in Review
82 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q2 2024, worth a combined $153M — down 31% from $220M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of IGMS and 13 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 40 added.
The largest buyer was Artal Group, adding an estimated $2.14M. The largest seller was RA Capital Management, exiting entirely with an estimated $9.05M sold.
- 82 institutional investors held IGM Biosciences (IGMS) as of Q2 2024, down from 87 in Q1 2024.
- Funds reported $153M of IGM Biosciences stock for Q2 2024, down 31% quarter-over-quarter.
- 13 funds opened new IGM Biosciences positions in Q2 2024 and 18 closed out, a net change of -5 holders.
- The largest IGM Biosciences buyer in Q2 2024 was Artal Group, an estimated $2.14M added.
- The largest IGM Biosciences seller in Q2 2024 was RA Capital Management, an estimated $9.05M sold.
Based on aggregated 13F filings for Q2 2024.